Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2006 Jul;92(7):926-32.
doi: 10.1136/hrt.2005.069484. Epub 2005 Dec 9.

Systemic sclerosis associated pulmonary hypertension: improved survival in the current era

M H Williams  1 , C Das, C E Handler, M R Akram, J Davar, C P Denton, C J Smith, C M Black, J G Coghlan
Affiliations

Systemic sclerosis associated pulmonary hypertension: improved survival in the current era

M H Williams et al. Heart. 2006 Jul.

Abstract

Objectives: To measure survival, haemodynamic function and functional class in patients with systemic sclerosis associated pulmonary arterial hypertension (SSc-PAH) in two treatment eras.

Methods: Six year longitudinal study of 92 consecutive patients with SSc-PAH diagnosed by cardiac catheterisation. Data were collected both prospectively and retrospectively. Patients were given basic treatment (diuretics, digoxin, oxygen and warfarin). Where clinically indicated, a prostanoid was used as advanced treatment (historical control group). From 2002, the range of treatments available expanded to include bosentan, which was generally the preferred treatment (current treatment era group). Survival was measured from the date of diagnosis of pulmonary hypertension by cardiac catheterisation. Six minute walking distance and haemodynamic function were measured at the time of diagnosis and at least one month after treatment was started.

Results: The historical control group comprised 47 patients, all of whom received basic treatment; 27 of these were also treated with prostanoids. The current treatment era group comprised 45 patients, all of whom received bosentan as preferred treatment. Kaplan-Meier survival in the historical control group was 68% at one year and 47% at two years. Survival in the current treatment era group was 81% and 71% (p = 0.016) at one and two years, respectively. Pulmonary vascular resistance increased in the historical control group (by 147 dyn.s.cm(-5)), whereas in the current treatment era group, it remained stable over an average of nine months (decrease of 16 dyn x s x cm(-5), p < 0.006).

Conclusion: Survival of selected patients with SSc-PAH has improved in the current treatment era. In contrast to patients treated historically with basic drugs and prostanoids, patients treated in the current treatment era had improved survival associated with a lack of deterioration in cardiac haemodynamic function.

PubMed Disclaimer

Conflict of interest statement

None of the authors have any financial association that can give conflict of interest. However, Drs Coghlan and Denton and Professor Black have unrestricted research grants from and have acted as advisors to pharmaceutical companies including Actelion, Genzyme and Schering. They have been investigators in clinical trials sponsored by these companies.

References

    1. Rich S, Rubin L J, Abenhail L.et al Executive summary from the world symposium on primary pulmonary hypertension (Evian, France, September 6–10, 1998). http://www.who.int/ned/cvd/pph.html (accessed 1 Feb 2002)
    1. Kawut S M, Taichman D B, Archer‐Chicko C L.et al Hemodynamics and survival in patients with pulmonary arterial hypertension related to systemic sclerosis. Chest 2003123344–350. - PubMed
    1. Pietra G G, Capron F, Stewart S.et al Pathologic assessment of vasculopathies in pulmonary hypertension. J Am Coll Cardiol 20044325S–32S. - PubMed
    1. Laughlin V V, Genthner D E, Panella M M.et al Reduction in pulmonary vascular resistance with long‐term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension. N Engl J Med 1998338273–277. - PubMed
    1. Badesch D B, Tapson V F, McGoon M D.et al Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. Ann Intern Med 2000132425–434. - PubMed

Publication types

MeSH terms